A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

Phase 2

Recruiting

• Conditions: Unresectable Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer
• Interventions: Biological: BNT113; Biological: Pembrolizumab

• Registration Number: NCT04534205
• Lead Sponsor: BioNTech SE

Brief Summary

An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.

This trial has two parts.

Part A, is an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.

Part B, is a randomized part to generate pivotal efficacy and safety data of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy in the first line setting in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing PD-L1 with CPS ≥1. Patients included in the Safety Run-In Phase of the trial (Part A) will not be randomized to Part B and will continue on-trial treatment (BNT113 plus pembrolizumab) within Part A.

For Part B, an optional pre-screening phase is available for all patients where patients' tumor samples may be submitted for central HPV16 DNA and central PD-L1 expression testing prior to screening into the main trial.

Patients will be treated with BNT113 in combination with pembrolizumab or with pembrolizumab monotherapy for approximately up to 24 months.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-08-27
• Study First Submitted QC: 2020-08-27
• Study First Posted: 2020-09-01
• Study Start: 2021-01-07
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-15
• Last Update Posted: 2025-05-16
• Primary Completion: 2029-04
• Study Completion: 2029-04

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

• Patients must sign the written pre-screening informed consent form (ICF) before any pre-screening procedures.
• Patients who present histologically confirmed recurrent or metastatic HPV16+ HNSCC that is considered incurable by local therapies.
• Patients who have a tumor that expresses PD-L1 [CPS ≥1] as determined by the European Conformity (CE)-marked/Food and Drug Administration-approved CDx PD-L1 immunohistochemistry 22C3 pharmDx performed according to the manufacturer's instructions for use.
• Patients must not have had prior systemic anticancer therapy administered in the incurable recurrent or metastatic setting. Systemic therapy which was completed more than 180 days prior to randomization, if given as part of multimodal treatment for locally advanced disease, is allowed.
• Patients who have measurable disease based on RECIST 1.1 as determined by the site and confirmed by BICR. Tumor lesions situated in a previously irradiated area may be considered measurable, if progression has been demonstrated in such lesions disease by RECIST 1.1.
• All patients must provide a tumor tissue sample (formalin fixed paraffin embedded [FFPE] blocks or both slides and curls) from archival tissue. Alternatively, a fresh biopsy sample could be provided if a biopsy sample is performed as part of the patient's standard clinical practice before the first dose of trial treatment. The sample should be preferably derived from a current site of metastatic or recurrent disease. Otherwise, a sample from the primary tumor can be submitted.

Key

Exclusion Criteria

Medical conditions:

• Patients present primary tumor site of nasopharynx (any histology).
• Patients with another primary malignancy that has not been in complete remission for at least 2 years, with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, non-invasive basal or non-invasive squamous cell skin cancer, localized prostate cancer, non-invasive superficial bladder cancer or breast ductal carcinoma in situ).

Prior/concomitant therapy:

• Patients who have received or currently receive the following therapy/medication:

  1. Chronic systemic immunosuppressive treatment including corticosteroid treatment (prednisone >10 mg daily orally [PO] or intravenously [IV], or equivalent) in the 7 days prior to the first dose of trial treatment.
  2. Prior treatment with other immune-modulating agents that was (a) within fewer than 4 weeks (28 days) or five half-lives of the agent (whichever is longer) prior to the first dose of BNT113, or (b) associated with immune-mediated AEs that have not resolved prior to the first dose of BNT113 or that pose an additional risk of on-trial complications, per investigator's assessment, or c) associated with toxicity that resulted in discontinuation of the immune-modulating agent and that poses an additional risk of on-trial complications, per investigator's assessment.
  3. Prior treatment with live attenuated vaccines within 4 weeks before the first dose of BNT113.
  4. Prior treatment with an investigational drug (including investigational vaccines) within 4 weeks or five half-lives of the agent (whichever is longer) before the planned first dose of BNT113.
  5. Ongoing treatment with therapeutic PO or IV antibiotics. Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) may be enrolled.

• Prior treatment with anti-cancer immunomodulating agents, such as blockers of programmed death receptor-1 (PD-1), PD-L1, tumor necrosis factor receptor superfamily member 9 (TNRSF9, 4 1BB, CD137), OX 40, therapeutic vaccines, cytokine treatments, or any investigational agent within 4 weeks or five half-lives of the agent (whichever is longer) before the first dose of BNT113.

• Treatment with non-systemic anti-cancer therapy (e.g., radiotherapy or surgery) within 2 weeks prior to randomization. Note: Prior treatment with bone resorptive therapy, such as bisphosphonates (e.g., pamidronate, zoledronic acid) and denosumab, is allowed.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Part A (Safety Run-In) - BNT113 + Pembrolizumab	BNT113	Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.
Part A (Safety Run-In) - BNT113 + Pembrolizumab	Pembrolizumab	Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab.
Part B (Randomized phase) - BNT113 + Pembrolizumab	BNT113	BNT113 in combination with pembrolizumab.
Part B (Randomized phase) - BNT113 + Pembrolizumab	Pembrolizumab	BNT113 in combination with pembrolizumab.
Part B (Randomized phase) - Pembrolizumab monotherapy	Pembrolizumab	Pembrolizumab monotherapy.

Primary Outcome Measures

Name	Time	Method
Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumab	up to 27 months	TEAE assessed according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) including Grade ≥3, serious, and fatal TEAEs, by relationship.
Part B - Overall survival (OS)	up to 48 months	OS defined as the time from randomization to death from any cause.
Part B - Progression-free survival (PFS)	up to 48 months	PFS defined as the time from randomization to the first objective tumor progression (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] assessed by the blinded independent central review \[BICR\]), or death from any cause, whichever occurs first.

Secondary Outcome Measures

Name	Time	Method
Part A and B - Overall response rate (ORR)	up to 48 months	ORR defined as the proportion of patients in whom a complete response (CR) or partial response (PR) (per RECIST 1.1 assessed by BICR and investigator) is observed as best overall response.
Part A and B - Duration of response (DOR)	up to 48 months	DOR defined as the time from first objective response (CR or PR per RECIST 1.1) to first occurrence of objective tumor progression (progressive disease \[PD\] per RECIST 1.1) or death from any cause, whichever occurs first. In Part A, assessment will be done by both BICR and investigator; in Part B, only by BICR.
Part A - Disease control rate (DCR)	up to 48 months	DCR defined as the proportion of patients in whom a CR or PR or stable disease (SD) (per RECIST 1.1, assessed at least 6 weeks after first dose by BICR and investigator) is observed as best overall response.
Part B - Progression free survival (PFS)	up to 48 months	PFS defined as the time from randomization to the first objective tumor progression (per RECIST 1.1 by investigator's assessment) or death from any cause, whichever occurs first.
Part B - PFS rate at 6 months	from randomization until 6 months after randomization	Defined as the proportion of patients without objective tumor progression (per RECIST 1.1 assessed by BICR and investigator) or death from any cause
Part B - PFS rate at 12 months	from randomization until 12 months after randomization	Defined as the proportion of patients without objective tumor progression (per RECIST 1.1 assessed by BICR and investigator) or death from any cause.
Part B - Occurrence of TEAEs - BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy	up to 27 months	TEAEs assessed according to CTCAE v5.0 including Grade ≥3, serious, and fatal TEAEs by relationship.
Part B - Occurrence of dose reduction, delay, and discontinuation of trial treatments due to TEAEs	up to 27 months	BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy.

Trial Locations

Locations (184)

California Research Institute; 🇺🇸 Los Angeles, California, United States

UCLA Cancer Care; 🇺🇸 Los Angeles, California, United States

Stanford Cancer Institute; 🇺🇸 Palo Alto, California, United States

Yale University; 🇺🇸 New Haven, Connecticut, United States

The George Washington Cancer Center; 🇺🇸 Washington, District of Columbia, United States

University of Miami Miller School of Medicine; 🇺🇸 Plantation, Florida, United States

University Cancer and Blood Center; 🇺🇸 Athens, Georgia, United States

Winship Cancer Institute; 🇺🇸 Atlanta, Georgia, United States

Norton Cancer Institute; 🇺🇸 Louisville, Kentucky, United States

Tufts Medical Center; 🇺🇸 Boston, Massachusetts, United States

The University of New Mexico Comprehensive Cancer Center; 🇺🇸 Albuquerque, New Mexico, United States

Montefiore Medical Center; 🇺🇸 Bronx, New York, United States

Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States

University of Cincinnati Cancer Center; 🇺🇸 Cincinnati, Ohio, United States

Providence Cancer Institute; 🇺🇸 Portland, Oregon, United States

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States

MultiCare Regional Cancer Center; 🇺🇸 Tacoma, Washington, United States

Centro de Oncología e Investigación Buenos Aires COIBA; 🇦🇷 Berazategui, Argentina

Hospital Britanico de Buenos Aires; 🇦🇷 Ciudad de Buenos Aires, Argentina

Hopital de la Timone; 🇫🇷 Marseille, France

Instituto de Oncologia de Cordoba; 🇦🇷 Córdoba, Argentina

Centro Oncologico Riojano Integral; 🇦🇷 La Rioja, Argentina

Centro de Investigacion Pergamino SA - Clinica Pergamino; 🇦🇷 Pergamino, Argentina

Instituto de Oncologia de Rosario; 🇦🇷 Rosario, Argentina

Sanatorio Britanico; 🇦🇷 Rosario, Argentina

CAIPO Centro para la Atencion Integral del Paciente Oncologico; 🇦🇷 San Miguel De Tucumán, Argentina

Clinica Viedma; 🇦🇷 Viedma, Argentina

Cancer Research SA; 🇦🇺 Adelaide, Australia

Bankstown-Lidcombe Hospital; 🇦🇺 Bankstown, Australia

Flinders Medical Centre; 🇦🇺 Bedford Park, Australia

Coffs Harbour Hospital; 🇦🇺 Coffs Harbour, Australia

St Vincent's Hospital; 🇦🇺 Fitzroy, Australia

Royal North Shore Hospital; 🇦🇺 Saint Leonards, Australia

John Flynn Private Hospital; 🇦🇺 Tugun, Australia

Southern Medical Day Care Centre; 🇦🇺 Wollongong, Australia

LKH - Univ. Klinikum Graz; 🇦🇹 Graz, Austria

Landeskrankenhaus/ Univ.-Kliniken Innsbruck; 🇦🇹 Innsbruck, Austria

HNO, Kopf-und Halschirurgie Ordensklinikum Linz Barmherzigen Schwestern; 🇦🇹 Linz, Austria

Uniklinikum Salzburg, Univ. Klinik fur Innere Medizin III; 🇦🇹 Salzburg, Austria

Universitair Ziekenhuis Brussel; 🇧🇪 Bruxelles, Belgium

Universitair Ziekenhuis Gent UZ Gent; 🇧🇪 Gent, Belgium

James Lind Centro de Investigación del Cáncer; 🇨🇱 Temuco, Chile

CHR de la Citadelle; 🇧🇪 Liège, Belgium

Fundação PIO XII - Hospital de Amor Barretos; 🇧🇷 Barretos, Brazil

Fundacao Universidade de Caxias do Sul - Instituto de Pesquisas em Saude IPS-UCS; 🇧🇷 Caxias Do Sul, Brazil

Hospital Erasto Gaertner; 🇧🇷 Curitiba, Brazil

Oncosite - Centro de Pesquisa Clinica em Oncologia; 🇧🇷 Ijuí, Brazil

Hospital Marcio Cunha; 🇧🇷 Ipatinga, Brazil

Irmandade Santa Casa de Misericordia de Porto Alegre Hospital Santa Rita; 🇧🇷 Porto Alegre, Brazil

Hospital Mae de Deus; 🇧🇷 Porto Alegre, Brazil

Hospital Sao Lucas da PUCRS; 🇧🇷 Porto Alegre, Brazil

Instituto Nacional de Cancer Jose de Alencar Gomes da Silva - INCA; 🇧🇷 Rio De Janeiro, Brazil

Hospital Sao Rafael; 🇧🇷 Salvador, Brazil

Hospital de Base de Sao Jose do Rio Preto; 🇧🇷 São José Do Rio Preto, Brazil

Instituto do Cancer do Estado de São Paulo; 🇧🇷 São Paulo, Brazil

IBCC - Instituto Brasileiro de Controle do Cancer; 🇧🇷 Vila Mariana, Brazil

Cross Cancer Institute; 🇨🇦 Edmonton, Canada

British Columbia Cancer Agency; 🇨🇦 Kelowna, Canada

Jewish General Hospital; 🇨🇦 Montreal, Canada

McGill University Health Centre; 🇨🇦 Montréal, Canada

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Canada

Centro de Estudios Clinicos SAGA; 🇨🇱 Santiago, Chile

Fundación Arturo López Pérez; 🇨🇱 Santiago, Chile

Fakultni Nemocnice Olomouc; 🇨🇿 Olomouc, Czechia

Hospital Na Bulovce (Nemocnice na Bulovce); 🇨🇿 Prague 8 - Liben, Czechia

CHU de BORDEAUX, Hopital Saint Andre; 🇫🇷 Bordeaux, France

CHU de Caen Normandie; 🇫🇷 Caen, France

Centre Georges Francois Leclerc; 🇫🇷 Dijon Cedex, France

Clinique Victor Hugo; 🇫🇷 Le Mans, France

Institut de Radiothérapie Hartmann, GCS CCConcorde; 🇫🇷 Levallois-Perret, France

Hopital Prive du Confluent; 🇫🇷 Nantes, France

Institut Curie; 🇫🇷 Paris, France

Institut Curie, Groupe Hospitalier Paris Saint-Joseph (GHPSJ); 🇫🇷 Paris, France

CHU de Tours Hopital Bretonneau; 🇫🇷 Tours, France

Hospital Gustave Roussy; 🇫🇷 Villejuif, France

Charite Universitätsklinikum Berlin - Campus Benjamin Franklin; 🇩🇪 Berlin, Germany

Krankenhaus Nordwest GmbH; 🇩🇪 Frankfurt am Main, Germany

SRH Wald-Klinikum Gera GmbH; 🇩🇪 Hamburg, Germany

Kath. Marien Krankenhaus gGmbH; 🇩🇪 Hamburg, Germany

Medizinische Hochschule Hannover (MHH); 🇩🇪 Hannover, Germany

Universitaetsklinik Heidelberg; 🇩🇪 Heidelberg, Germany

Klinik für HNO-Heilkunde, Kopf- und Hals-Chirurgie; 🇩🇪 Köln, Germany

Universitätsklinikum Leipzig; 🇩🇪 Leipzig, Germany

UNIVERSITAETSMEDIZIN der Johannes Gutenberg-Universitaet Mainz; 🇩🇪 Mainz, Germany

Klinikum rechts der Isar der TUM; 🇩🇪 München, Germany

Univeritätsklinikum Münster; 🇩🇪 Münster, Germany

Universitaetsmedizin Rostock - Medizinische Klink III (Hamatologie, Onkologie, Palliativmedizin); 🇩🇪 Rostock, Germany

Caritas Klinikum Saarbrucken St. Theresia; 🇩🇪 Saarbruecken, Germany

Medizinische Universitaetsklinik Tuebingen; 🇩🇪 Tübingen, Germany

Universitaetsklinikum Wuerzburg; 🇩🇪 Würzburg, Germany

Central Hospital of Northern Pest - Military Hospital; 🇭🇺 Budapest, Hungary

Uzsoki Utcai Korhaz Onkologiai Osztaly; 🇭🇺 Budapest, Hungary

DEKK Onkologiai Klinika; 🇭🇺 Debrecen, Hungary

Zala Megyei S. Rafael Korhaz; 🇭🇺 Zalaegerszeg, Hungary

Rambam Health Clinical; 🇮🇱 Haifa, Israel

Clinica Universidad de Navarra - Madrid (CUN-M); 🇪🇸 Madrid, Spain

Hospital Universitario Fundacion Jimenez Diaz; 🇪🇸 Madrid, Spain

Hadassah Medical Center - Sharett Institute of Oncology; 🇮🇱 Jerusalem, Israel

Rabin Medical Center; 🇮🇱 Petah tikva, Israel

Tel Aviv Sourasky Medical Center; 🇮🇱 Tel Aviv, Israel

ASST Spedali Civili Brescia; 🇮🇹 Brescia, Italy

Mater Salutis Hospital AULSS 9 della Regione Veneto; 🇮🇹 Legnago, Italy

IRCCS Ospedale San Raffaele; 🇮🇹 Milano, Italy

IRCCS Istituto Europeo di Oncologia; 🇮🇹 Milano, Italy

Ospedale del Mare; 🇮🇹 Napoli, Italy

A.O.U. Maggiore della Carita; 🇮🇹 Novara, Italy

Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte; 🇮🇹 Siena, Italy

Azienda Sanitaria Universitaria Integrata Friuli Centrale - Presidio ospedaliero di Udine; 🇮🇹 Udine, Italy

Chungnam National University Hospital; 🇰🇷 Daejeon, Korea, Republic of

Konyang University Hospital; 🇰🇷 Daejeon, Korea, Republic of

Chonnam National University Hwasun Hospital; 🇰🇷 Hwasun, Korea, Republic of

Korea University Anam Hospital; 🇰🇷 Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System; 🇰🇷 Seoul, Korea, Republic of

The Catholic University of Korea, Seoul ST. Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of

The Catholic University of Korea St. Vincent's Hospital; 🇰🇷 Suwon-si, Korea, Republic of

Ajou University Hospital; 🇰🇷 Suwon-si, Korea, Republic of

Centro de Estudios y Prevención del Cáncer (CEPREC); 🇲🇽 Tuxtla Gutiérrez, Region Chiapas, Mexico

Centro Estatal de Cancerologia de Chihuahua; 🇲🇽 Chihuahua, Mexico

Cryptex Investigacion SA de CV; 🇲🇽 Ciudad De México, Mexico

Hospital Civil de Guadalajara Fray Antonio Alcalde; 🇲🇽 Guadalajara, Mexico

Consultorio del Dr. Joaquín Gabriel Reinoso Toledo; 🇲🇽 Monterrey, Mexico

Hospital Universitario "Dr Jose Eleuterio Gonzalez" Centro Universitario contra el Cáncer; 🇲🇽 Monterrey, Mexico

Oaxaca Site Management Organization S. C.; 🇲🇽 Oaxaca de Juarez, Mexico

Sociedad de Metabolismo y Corazón S.C.; 🇲🇽 Veracruz, Mexico

Centro de Atencion e Investigacion Clinica en Oncologia (CAICO); 🇲🇽 Yucatán, Mexico

Uniwersyteckie Centrum Kliniczne; 🇵🇱 Gdańsk, Poland

Szpitale Pomorskie Sp.zo.o; 🇵🇱 Gdynia, Poland

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie; 🇵🇱 Gliwice, Poland

Przychodnia Lekarska KOMED Roman Karaszewski; 🇵🇱 Konin, Poland

MCM Pratia Krakow; 🇵🇱 Kraków, Poland

Centrum Medyczne Pratia Poznań; 🇵🇱 Poznań, Poland

Wojskowy Szpital Kliniczny z Poliklinika SP ZOZ; 🇵🇱 Wrocław, Poland

Centro Clinico Academico; 🇵🇹 Braga, Portugal

Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E.; 🇵🇹 Coimbra, Portugal

Centro Hospitalar de Vila Nova de Gaia/Espinho; 🇵🇹 Gaia, Portugal

Centro Hospitalar Universitario Lisboa Norte; 🇵🇹 Lisboa, Portugal

Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E; 🇵🇹 Porto, Portugal

Hospital Clinic Barcelona; 🇪🇸 Barcelona, Spain

Hospital Univ. Dr. Josep Trueta; 🇪🇸 Girona, Spain

Complejo Hospitalario de Jaen; 🇪🇸 Jaén, Spain

Hospital Universitario La Paz; 🇪🇸 Madrid, Spain

Hospital Universitario Puerta de Hierro Majadahonda; 🇪🇸 Majadahonda, Spain

Hospital Regional de Malaga; 🇪🇸 Malaga, Spain

Hospital Universitario Son Espases; 🇪🇸 Palma de Mallorca, Spain

Clinica Universidad de Navarra - Pamplona (CUN-P); 🇪🇸 Pamplona, Spain

Hospital La Fe; 🇪🇸 Valencia, Spain

Hospital Miguel Servet; 🇪🇸 Zaragoza, Spain

Sahlgrenska University Hospital; 🇸🇪 Goteborg, Sweden

Skane University Hospital; 🇸🇪 Lund, Sweden

Norrlands University Hospital; 🇸🇪 Umeå, Sweden

Changhua Christian Hospital; 🇨🇳 Changhua, Taiwan

Chang Bing Show Chwan Memorial Hospital; 🇨🇳 Changhua, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital; 🇨🇳 Kaohsiung City, Taiwan

Chang Gung Memorial Hospital-Kaohsiung Branch; 🇨🇳 Kaohsiung, Taiwan

Taichung Veterans General Hospital; 🇨🇳 Taichung, Taiwan

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan

Taipei Veterans General Hospital; 🇨🇳 Taipei, Taiwan

Medical Park Seyhan Hospital; 🇹🇷 Adana, Turkey

Ankara Bilkent Sehir Hastanesi; 🇹🇷 Ankara, Turkey

Hacettepe University Cancer Institute; 🇹🇷 Ankara, Turkey

Trakya University; 🇹🇷 Edirne, Turkey

Istanbul Universitesi Onkoloji Enstitusu; 🇹🇷 Istanbul, Turkey

Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty; 🇹🇷 Istanbul, Turkey

Medipol Mega Universite Hastanesi; 🇹🇷 Istanbul, Turkey

Istanbul Medeniyet University Medical Faculty; 🇹🇷 Istanbul, Turkey

Ege Universitesi Tip Fakultesi Hastanesi - Tulay Aktas Onkoloji Hastanesi; 🇹🇷 İzmir, Turkey

Medical Park - Izmir Hastanesi; 🇹🇷 İzmir, Turkey

Inonu Universitesi - Turgut Ozal Tip Merkezi; 🇹🇷 Malatya, Turkey

Baskent University; 🇹🇷 Yüreğir, Turkey

Aberdeen Royal Infirmary; 🇬🇧 Aberdeen, United Kingdom

University Hospitals Birmingham, Queen Elizabeth Hospital; 🇬🇧 Birmingham, United Kingdom

Velindre Cancer Centre; 🇬🇧 Cardiff, United Kingdom

Beatson West of Scotland Cancer Centre; 🇬🇧 Glasgow, United Kingdom

Leeds Teaching Hospitals NHS Trust (St James's University Hospital); 🇬🇧 Leeds, United Kingdom

The Clatterbridge Cancer Centre; 🇬🇧 Liverpool, United Kingdom

University College London Hospitals; 🇬🇧 London, United Kingdom

Guy's Cancer Centre, Guy's Hospital; 🇬🇧 London, United Kingdom

The Royal Marsden Hospital NHS Foundation Trust - Fulham Road; 🇬🇧 London, United Kingdom

Nottingham University Hospitals NHS Trust; 🇬🇧 Nottingham, United Kingdom

Oxford Cancer Centre; 🇬🇧 Oxford, United Kingdom

Royal Preston Hospital Lancashire Teaching Hospitals NHS Foundation Trust; 🇬🇧 Preston, United Kingdom

University Hospital Southampton NHS Foundation Trust; 🇬🇧 Southampton, United Kingdom

Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust; 🇬🇧 Stevenage, United Kingdom

The Royal Marsden Hospital - Sutton; 🇬🇧 Sutton, United Kingdom